33 related articles for article (PubMed ID: 23609324)
1. Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression.
Revel M; Rezola Artero M; Hamidi H; Grunenwald A; Blasco L; Vano YA; Marie Oudard S; Sanchez-Salas R; Macek P; Rodriguez Sanchez L; Cathelineau X; Vedié B; Sautes-Fridman C; Herman Fridman W; Roumenina LT; Dragon-Durey MA
Oncoimmunology; 2024; 13(1):2328433. PubMed ID: 38487624
[TBL] [Abstract][Full Text] [Related]
2. Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.
Maas M; Kurcz A; Hennenlotter J; Scharpf M; Fend F; Walz S; Stühler V; Todenhöfer T; Stenzl A; Bedke J; Rausch S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982302
[TBL] [Abstract][Full Text] [Related]
3. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.
Bao S; Darvishi M; H Amin A; Al-Haideri MT; Patra I; Kashikova K; Ahmad I; Alsaikhan F; Al-Qaim ZH; Al-Gazally ME; Kiasari BA; Tavakoli-Far B; Sidikov AA; Mustafa YF; Akhavan-Sigari R
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7945-7968. PubMed ID: 36905421
[TBL] [Abstract][Full Text] [Related]
4. Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).
Wang W; Gan Z; Liu Q; Yan S; Mulati R; Wang Y
Bioengineered; 2021 Dec; 12(1):2957-2969. PubMed ID: 34180759
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced lncHILAR promotes renal cancer metastasis via ceRNA for the miR-613/206/ 1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway.
Hu G; Ma J; Zhang J; Chen Y; Liu H; Huang Y; Zheng J; Xu Y; Xue W; Zhai W
Mol Ther; 2021 Oct; 29(10):2979-2994. PubMed ID: 34058384
[TBL] [Abstract][Full Text] [Related]
6. Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma.
Petitprez F; Ayadi M; de Reyniès A; Fridman WH; Sautès-Fridman C; Job S
Front Oncol; 2021; 11():643065. PubMed ID: 33996558
[No Abstract] [Full Text] [Related]
7. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer.
Bihorel S; Raddad E; Fiedler-Kelly J; Stille JR; Hing J; Ludwig E
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):614-624. PubMed ID: 28643374
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
[TBL] [Abstract][Full Text] [Related]
10. Renal Cancer Stem Cells: Characterization and Targeted Therapies.
Peired AJ; Sisti A; Romagnani P
Stem Cells Int; 2016; 2016():8342625. PubMed ID: 27293448
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of High CXCR4 Expression in Renal Cell Carcinoma: A System Review and Meta-Analysis.
Du Y; Long Q; Guan B; Mu L
Dis Markers; 2015; 2015():568980. PubMed ID: 26526157
[TBL] [Abstract][Full Text] [Related]
12. A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization.
Nowicka AM; Häuselmann I; Borsig L; Bolduan S; Schindler M; Schraml P; Heikenwalder M; Moch H
Oncogene; 2016 Jun; 35(24):3125-38. PubMed ID: 26500060
[TBL] [Abstract][Full Text] [Related]
13. Biology of renal tumour cancer stem cells applied in medicine.
Matak D; Szymanski L; Szczylik C; Sledziewski R; Lian F; Bartnik E; Sobocinska A; Czarnecka AM
Contemp Oncol (Pozn); 2015; 19(1A):A44-51. PubMed ID: 25691821
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 over-expression and survival in cancer: a system review and meta-analysis.
Zhao H; Guo L; Zhao H; Zhao J; Weng H; Zhao B
Oncotarget; 2015 Mar; 6(7):5022-40. PubMed ID: 25669980
[TBL] [Abstract][Full Text] [Related]
15. The intricate role of CXCR4 in cancer.
Chatterjee S; Behnam Azad B; Nimmagadda S
Adv Cancer Res; 2014; 124():31-82. PubMed ID: 25287686
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma.
Li G; Badin G; Zhao A; Gentil-Perret A; Tostain J; Péoc'h M; Gigante M
Histol Histopathol; 2013 Sep; 28(9):1217-22. PubMed ID: 23609324
[TBL] [Abstract][Full Text] [Related]
17. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
[TBL] [Abstract][Full Text] [Related]
18. ITGA2B and ITGA8 are predictive of prognosis in clear cell renal cell carcinoma patients.
Lu X; Wan F; Zhang H; Shi G; Ye D
Tumour Biol; 2016 Jan; 37(1):253-62. PubMed ID: 26198048
[TBL] [Abstract][Full Text] [Related]
19. High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma.
Wang J; Xu Y; Zhu L; Zou Y; Kong W; Dong B; Huang J; Chen Y; Xue W; Huang Y; Zhang J
PLoS One; 2016; 11(11):e0166231. PubMed ID: 27861513
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
